Sleep Apnea Market to Witness Promising Upswing by 2034, DelveInsight Forecasts

The Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sleep Apnea pipeline products will significantly revolutionize the Sleep Apnea market dynamics.

DelveInsight's "Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Sleep Apnea, historical and forecasted epidemiology as well as the Sleep Apnea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sleep Apnea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sleep Apnea Market Forecast
https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Sleep Apnea Market Report:
• The Sleep Apnea market size was valued approximately USD 661 million in 2025 and is anticipated to reach USD 5,681 million by 2034 with a CAGR of 27% during the study period (2020-2034).
• In July 2025, Apnimed reported positive topline findings from LunAIRo, its second Phase 3 trial of AD109 (aroxybutynin 2.5 mg, atomoxetine 75 mg) in adults with obstructive sleep apnea. Earlier, in May, the company shared results from its SynAIRgy trial of AD109.T
• In May 2025, Apnimed reported positive Phase III SynAIRgy trial results for AD109, an oral OSA therapy. The study achieved its primary endpoint, demonstrating a significant reduction in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo. Effectiveness was observed across all severities of OSA and various weight groups. AD109 was well-tolerated, with no serious treatment-related adverse events. These findings support AD109's potential as a first-in-class oral treatment for OSA.
• In Jan 2025, Mineralys Therapeutics, Inc. announced that the FDA has approved its IND application for a Phase 2 clinical trial to assess lorundrostat for the treatment of Sleep Apnea (OSA) and hypertension. The trial is set to begin in the first quarter of 2025.
• In December 2024, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Zepbound® (tirzepatide) as the first and only prescription treatment for adults with moderate-to-severe Sleep Apnea (OSA) and obesity. Zepbound is intended to help alleviate sleep disorders in adults affected by both OSA and obesity.
• In June 2024, Eli Lilly and Company (NYSE: LLY) shared detailed findings from the SURMOUNT-OSA Phase III clinical trials, which assessed tirzepatide injection (10 mg or 15 mg) for treating moderate-to-severe Sleep Apnea (OSA) in adults with obesity, both with and without positive airway pressure (PAP) therapy. Lilly has submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the US Food and Drug Administration (FDA) and plans to begin submissions to other global regulatory authorities in the coming weeks.
• In April 2024, Incannex's IHL-42X, a cannabinod-based combination product, is progressing into phase II/III trials for Sleep Apnea (OSA). Early results have shown promise, enhancing its market potential. The trials, which will begin in the US and expand to Europe, are designed to tackle patient non-compliance with PAP devices.
• In May 2024, Incannex Healthcare Inc., a pharmaceutical company focused on developing innovative medicinal cannabinod and psychedelic therapies, announced that patient dosing has begun in its Phase II/III clinical trial to evaluate the safety and efficacy of IHL-42X in patients with Sleep Apnea (OSA).
• Between 2025 and 2034, pipeline therapies including Eli Lilly's retatrutide and orforglipron, Incannex's IHL-42X, and Apnimed's AD109, among others, are anticipated to fuel growth in the sleep apnea market.
• The sleep apnea treatment pipeline is advancing quickly, mainly targeting OSA. Key candidates include Eli Lilly's retatrutide and orforglipron, Incannex's IHL-42X, and Apnimed's AD109. Interestingly, SASS-001 from Shionogi Apnimed Sleep Science stands out as the only candidate currently focused on CSA.
• In 2024, the sleep apnea market across the EU4 and the UK was valued at around USD 120 million, representing nearly 20% of the total 7MM market.
• In 2024, Japan's sleep apnea market was valued at around USD 20 million.
• In 2024, the total number of diagnosed prevalent sleep apnea cases in the 7MM was estimated at around 29 million.
• In 2024, sleep apnea cases in the 7MM were about 15.8 million for mild and 13 million for moderate to severe severity.
• In 2024, obstructive sleep apnea (OSA) represented nearly 92% of all prevalent sleep apnea cases.
• In 2024, about 92% of total sleep apnea cases were attributed to obstructive sleep apnea (OSA).
• Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others
• Key Sleep Apnea Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others
• The Sleep Apnea epidemiology based on gender analyzed that in 2022, 61% cases of OSA were of males, while 39% cases were of Females in the 7MM
• The Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sleep Apnea pipeline products will significantly revolutionize the Sleep Apnea market dynamics.

Sleep Apnea Overview
Sleep apnea is a sleep disorder in which breathing repeatedly stops and starts during sleep. It leads to poor sleep quality, loud snoring, and daytime fatigue. The most common types are obstructive sleep apnea (OSA), caused by airway blockage, and central sleep apnea (CSA), caused by the brain not sending proper signals to control breathing. If untreated, it can increase the risk of high blood pressure, heart disease, stroke, and diabetes.

Get a Free sample for the Sleep Apnea Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/sleep-apnea-market

Sleep Apnea Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sleep Apnea Epidemiology Segmentation:
The Sleep Apnea market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Sleep Apnea
• Prevalent Cases of Sleep Apnea by severity
• Gender-specific Prevalence of Sleep Apnea
• Diagnosed Cases of Episodic and Chronic Sleep Apnea

Download the report to understand which factors are driving Sleep Apnea epidemiology trends @ Sleep Apnea Epidemiology Forecast
https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sleep Apnea Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sleep Apnea market or expected to get launched during the study period. The analysis covers Sleep Apnea market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sleep Apnea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sleep Apnea Therapies and Key Companies
• AD109 (Aroxybutynin + Atomoxetine): Apnimed
• Retatrutide: Eli Lilly and Company
• Orforglipron: Eli Lilly and Company
• IHL-42X (Acetazolamide + dronabinol): Incannex Healthcare
• ZEPBOUND/ MOUNJARO (tirzepatide): Eli Lilly and Company
• SUNOSI (solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
• OZAWADE (Pitolisant): Bioprojet

Discover more about therapies set to grab major Sleep Apnea market share @ Sleep Apnea Treatment Landscape
https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sleep Apnea Market Drivers
• Increase in prevalence of Sleep Apnea (OSA), rising awareness of the disorder are some of the important factors that are fueling the Sleep Apnea Market.

Sleep Apnea Market Barriers
• However, lack of Approved Drugs, complexity of OSA pathogenesis and other factors are creating obstacles in the Sleep Apnea Market growth.

Scope of the Sleep Apnea Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others
• Key Sleep Apnea Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others
• Sleep Apnea Therapeutic Assessment: Sleep Apnea current marketed and Sleep Apnea emerging therapies
• Sleep Apnea Market Dynamics: Sleep Apnea market drivers and Sleep Apnea market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Sleep Apnea Unmet Needs, KOL's views, Analyst's views, Sleep Apnea Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.